Cargando…
Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond
The coronavirus disease 2019 (COVID-19) pandemic has led to the deprioritization of non-emergency services, such as oral food challenges and the initiation of oral immunotherapy (OIT) for food-allergic children. Recent studies have suggested that home-based peanut OIT could be a safe and effective o...
Autores principales: | Chua, Gilbert T., Chan, Edmond S., Soller, Lianne, Cook, Victoria E., Vander Leek, Timothy K., Mak, Raymond |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974914/ https://www.ncbi.nlm.nih.gov/pubmed/35387028 http://dx.doi.org/10.3389/falgy.2021.725165 |
Ejemplares similares
-
Risk factors associated with safety of preschool peanut oral immunotherapy
por: Karunakaran, Duva, et al.
Publicado: (2023) -
Transitioning peanut oral immunotherapy to clinical practice
por: Lazizi, S., et al.
Publicado: (2022) -
Transitioning from epicutaneous to oral peanut immunotherapy
por: Wong, Lauren, et al.
Publicado: (2023) -
Differences in Linear Epitopes of Ara h 9 Recognition in Peanut Allergic and Tolerant, Peach Allergic Patients
por: Sánchez-Ruano, L., et al.
Publicado: (2022) -
Immune signatures predicting the clinical outcome of peanut oral immunotherapy: where we stand
por: Wanniang, Naphisabet, et al.
Publicado: (2023)